Diana Ernst, RPh, Author at MPR
Diana Ernst, RPh

Diana Ernst, RPh

Editorial Director https://www.empr.com
Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Doravirine Regimens Approved for Use in Virologically-Suppressed HIV Patients

The Food and Drug Administration (FDA) has approved Pifeltro (doravirine; Merck), in combination with other antiretroviral agents, and Delstrigo (doravirine, lamivudine, tenofovir disoproxil fumarate; Merck) for the treatment of HIV-1 infection in adult patients to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen…

Antibiotic Use May Impact PFS, Overall Survival in Lung Cancer Patients Treated With Pembrolizumab

In patients with naïve advanced non-small cell lung cancer (NSCLC) and high PD-LI expression who are treated with pembrolizumab, the use of intravenous (IV) antibiotics may negatively impact progression free survival (PFS) and overall survival, according to research presented at the IASLC 2019 World Conference on Lung Cancer. To evaluate the effect of antibiotics on…

Combination Treatment Approved for Advanced Endometrial Carcinoma

The Food and Drug Administration (FDA) has approved the combination of pembrolizumab (Keytruda; Merck), a human programmed death receptor-1 (PD-1)-blocking antibody, and lenvatinib (Lenvima; Eisai), a kinase inhibitor, for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic…

Secukinumab Effective in Axial Spondyloarthritis, According to 16-Week Trial Data

A phase 3 trial evaluating the efficacy and safety of secukinumab in patients with non-radiographic axial spondyloarthritis (nr-axSpA) met its 16-week primary end point, according to Novartis.  The PREVENT trial is an ongoing 2-year placebo-controlled study that enrolled patients with active nr-axSpA who had been on at least 2 different nonsteroidal anti-inflammatory drugs with an…

FDA Committee Votes on Palforzia for Peanut Allergy

The FDA’s Allergenic Products Advisory Committee voted in favor of the approval of Palforzia (AR101; Aimmune Therapeutics) as a treatment to reduce the incidence and severity of allergic reactions, including anaphylaxis, after accidental exposure to peanut in patients 4 through 17 years old with a confirmed diagnosis of peanut allergy.


FDA: Nitrosamine Impurity Identified in Commonly Used Acid Suppressant

According to the Food and Drug Administration (FDA), a nitrosamine impurity, N-nitrosodimethylamine (NDMA), has been identified in some samples of ranitidine. NDMA was one of several nitrosamine impurities implicated in the massive recall of angiotensin II receptor blockers (ARBs) since last year.  NDMA is classified as a probable human carcinogen; the impurity was identified following…

FDA Approves First-in-Class Treatment for IBS-C

The Food and Drug Administration (FDA) has approved Ibsrela (tenapanor; Ardelyx) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Ibsrela is a locally-acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium.…